| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the University of Southern California, Los Angeles, CA (Dr. Waters); Barrow Neurological Institute, Phoenix, AZ (Dr. Kurth); St John Regional Hospital, St John, New Brunswick (Dr. Bailey); University of Miami School of Medicine, Miami, FL (Dr. Shulman); Sinai Clinical Neuroscience Research Center, West Bloomfield, MI (Dr. LeWitt); and Hoffmann-La Roche, Nutley, NJ (Drs. Dorflinger, Deptula, and Pedder).
Address correspondence and reprint requests to Dr Waters, University of Southern California School of Medicine, Division of Movement Disorders, 1510 San Pablo Street #615, Los Angeles, CA 90033.
In this double-blind, placebo-controlled trial, we investigated the effect of the catechol-O-methyltransferase inhibitor tolcapone 100 or 200 mg three times daily on activities of daily living and motor function in 298 patients with parkinsonism receiving levodopa but without motor fluctuations. At 6 months, both dosages of tolcapone produced significant reductions in the Unified Parkinson's Disease Rating Scale scores for activities of daily living (Subscale II) and motor function (Subscale III) and in the total score for Subscales I to III. These improvements were maintained up to the 12-month assessment. At 6 months, both tolcapone groups had changes in levodopa dosage that were significantly different from placebo: the tolcapone groups had decreases in mean total daily dose of levodopa, whereas the placebo group had a mean increase. Tolcapone was well tolerated. The principal adverse events were levodopa-related, but these were generally mild or moderate. Diarrhea was the most frequent nondopaminergic adverse event. Tolcapone appears to be beneficial in the treatment of patients with parkinsonism who have not yet developed motor fluctuations.
See Appendix for members of the Tolcapone Stable Study Group.
Supported by F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Presented in part at the 48th annual meeting of the American Academy of Neurology, San Francisco, March, 1996.
Received December 27, 1996. Accepted in final form April 10, 1997.
This article has been cited by other articles:
|
|
 |
|
  C. W. Olanow, M. B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Waters and J. J. Chen Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off'' Journal of Pharmacy Practice, August 1, 2008; 21(4): 254 - 261. [Abstract] [PDF]
|
|
|
|
 |
|
 A J Lees, V Ratziu, E Tolosa, and W H Oertel Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 944 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Olanow, K. Kieburtz, M. Stern, R. Watts, J. W. Langston, M. Guarnieri, J. Hubble, and for the US01 Study Team Double-blind, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Stable Parkinson Disease Arch Neurol, October 1, 2004; 61(10): 1563 - 1568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Brooks Safety and tolerability of COMT inhibitors Neurology, January 13, 2004; 62(90011): S39 - 46. [Abstract] [Full Text]
|
|
|
|
|
|
D J Brooks and H Sagar Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1071 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Bonifacio, M. Archer, M. L. Rodrigues, P. M. Matias, D. A. Learmonth, M. A. Carrondo, and P. Soares-da-Silva Kinetics and Crystal Structure of Catechol-O-Methyltransferase Complex with Co-Substrate and a Novel Inhibitor with Potential Therapeutic Application Mol. Pharmacol., October 1, 2002; 62(4): 795 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]
|
|
|
|
|
|
C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colcher and M. B. Stern Therapeutics in the Neurorehabilitation of Parkinson's Disease Neurorehabil Neural Repair, December 1, 1999; 13(4): 205 - 218. [Abstract] [PDF]
|
|
|
|
 |
|
 P. T. Mannisto and S. Kaakkola Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors Pharmacol. Rev., December 1, 1999; 51(4): 593 - 628. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
